Comparison 3.

Budesonide and formoterol (BDF) versus formoterol (F), secondary outcomes

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Quality of life ‐ SGRQ (change scores)	4	3442	SGRQ (Random, 95% CI)	‐2.69 [‐3.82, ‐1.55]
2 Quality of life ‐ SGRQ (change scores)	4		Mean Difference (IV, Random, 95% CI)	Totals not selected
3 Change from baseline in St George's Respiratory Questionnaire (domain ‐ symptoms)	2	2233	Mean Difference (IV, Random, 95% CI)	‐3.43 [‐5.13, ‐1.72]
4 Change from baseline in St George's Respiratory Questionnaire (domain ‐ activity)	2	2215	Mean Difference (IV, Random, 95% CI)	‐1.57 [‐2.87, ‐0.27]
5 Change from baseline in St George's Respiratory Questionnaire (domain ‐ impact)	2	2222	Mean Difference (IV, Random, 95% CI)	‐2.28 [‐3.60, ‐0.95]
6 Mean FEV1 (% increase from baseline)	1		Std. Mean Difference (IV, Random, 95% CI)	Totals not selected
7 Mean change from baseline in pre dose FEV1 to the average over the randomised treatment period.	2	1203	Mean Difference (IV, Random, 95% CI)	0.05 [0.00, 0.09]
8 Symptoms ‐ breathlessness (change scores)	2	2308	Mean Difference (IV, Random, 95% CI)	‐0.07 [‐0.12, ‐0.01]
9 Change from baseline in cough score	2	2308	Mean Difference (IV, Random, 95% CI)	‐0.06 [‐0.11, ‐0.00]
10 Change from baseline in rescue medication usage (puffs/day)	2	2310	Mean Difference (IV, Random, 95% CI)	‐0.33 [‐0.57, ‐0.09]
11 Adverse events ‐ 'serious' events	4	3243	Odds Ratio (M‐H, Random, 95% CI)	0.92 [0.69, 1.25]
12 Adverse events ‐ candidiasis	2		Odds Ratio (M‐H, Random, 95% CI)	Subtotals only
13 Withdrawals due to adverse events	4	3243	Odds Ratio (M‐H, Random, 95% CI)	0.88 [0.65, 1.19]
14 Withdrawals due to worsening COPD symptoms	2	918	Odds Ratio (M‐H, Random, 95% CI)	0.49 [0.32, 0.74]